Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo

Fig. 3

Overexpression of HMGB1 increases the resistance to sorafenib in HepG2 cells. (*p < 0.05; **p < 0.01). Ai qPCR and Aii western blot analyses show the overexpression of HMGB1 in Plvx-HMGB1 cells compared with that in Plvx-control HepG2 cells. B HMGB1 overexpression affects drug sensitivity at different sorafenib doses as determined by a CCK-8 assay. C Plvx-HMGB1 cells and Plvx-control HepG2 cells were treated with 5 μM sorafenib (treatment) or DMSO at same volume (control) for 48 h. The percentage of Annexin V positive cells was measured as an indicator of early and late apoptotic cells. D c-PARP was examined to measure the apoptosis levels in HMGB1-overexpressing HepG2 cells and Plvx-Control HepG2 cells

Back to article page